Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 10:03 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 1,666 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: High Dose Drug A Clear all

Conditions: AML, Adult Recurrent, MDS
Interventions: DVX201; Biological
Lead sponsor: Coeptis Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Metastatic Neuroendocrine Prostate Cancer
Interventions: [68Ga]Ga-PSMA-11, [68Ga]GA-DOTA-TATE, [68Ga]Ga-NeoB, [177Lu]Lu-PSMA-617, [177Lu]Lu-DOTA-TATE, [177Lu]Lu-NeoB, L-Lysine HCl-L-Arginine HCl, 2.5 %,, Gonadotropin-releasing hormone (GnRH) analogues, GnRH antagonists, Antiemetics & antinauseants, Metoclopramide; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Omaha, Nebraska • New York, New York

Conditions: Obesity or Overweight
Interventions: AZD9550, AZD6234, Placebo comparator; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 377 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 29
States / cities: Dothan, Alabama • Vestavia Hills, Alabama • Cerritos, California + 26 more

Conditions: Breast Cancer, Cardiotoxicity
Interventions: antihypertensive medications, Blood pressure measurement, Echocardiogram, Symptom-limited cardiopulmonary exercise test, Quality of Life Measures, Biomarkers; Other · Diagnostic Test
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Prostate Cancer, Prostate Disease
Interventions: Nivolumab, Brachytherapy, External Beam Radiation Therapy, Androgen Deprivation Therapy; Drug · Radiation
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Alpha 1 Antitrypsin Deficiency
Interventions: Alpha-1 Antitrypsin (human); Drug
Lead sponsor: Michael Campos, MD; Other
Eligibility: 18 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Danirixin 35 mg tablets, Placebo, Metered dose inhaler (MDI) sensor device, Rescue medication; Drug · Device
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years to 76 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 11
States / cities: Birmingham, Alabama • San Diego, California • Torrance, California + 8 more

Conditions: Myeloid Diseases
Interventions: DFV890; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 11
States / cities: Stanford, California • Tampa, Florida • Chicago, Illinois + 7 more

Conditions: Marijuana Impairment, Alcohol Impairment
Interventions: Low Marijuana, Hash, THC, or Grass, High Marijuana, Hash, THC, or Grass, Placebo, 0.05 BAC Alcohol, 0.08 BAC Alcohol; Drug
Lead sponsor: Yale University; Other
Eligibility: 21 Years to 40 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Plaque Psoriasis
Interventions: ORKA-001; Drug
Lead sponsor: Oruka Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 26
States / cities: Phoenix, Arizona • North Little Rock, Arkansas • Fountain Valley, California + 20 more

Conditions: Ovarian Neoplasms, Endometrial Cancer, Endometrial Neoplasm
Interventions: BMX-001, Paclitaxel (Taxol); Drug
Lead sponsor: BioMimetix JV, LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Pediatric Tumor of CNS, Pediatric Tumor of Brain, Diffuse Midline Glioma, H3 K27M-Mutant, Pediatric Tumor of Brain Stem, Pineocytoma, Choroid Plexus Carcinoma, Childhood, Spinal Cord Tumor, High Grade Glioma
Interventions: NEO100; Drug
Lead sponsor: Neonc Technologies, Inc.; Industry
Eligibility: 5 Years to 18 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Orange, California

Conditions: Ovarian Cancer
Interventions: TUB-040 + Carbo + BEV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Los Angeles, California • East Brunswick, New Jersey • New York, New York

Conditions: Blood Glucose, Insulin Sensitivity, Dietary Fiber
Interventions: Medium-fiber bar, High-fiber bar, Control bar (0 g fiber); Other
Lead sponsor: Midwest Center for Metabolic and Cardiovascular Research; Other
Eligibility: 18 Years to 65 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Boca Raton, Florida • Chicago, Illinois

Conditions: Metastatic Breast Cancer
Interventions: High-dose chemotherapy; Procedure
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1987 – 2002
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Sarcoma, Refractory Sarcoma
Interventions: Pazopanib, Irinotecan, Temozolomide; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 6 Years to 30 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 3
States / cities: Oakland, California • San Francisco, California • Boston, Massachusetts

Conditions: PONV
Interventions: Palonosetron only, Palonosetron with Dexamethasone; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 55 Years
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Stable Angina Pectoris
Interventions: T89 capsule, Placebo capsule; Drug
Lead sponsor: Tasly Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 765 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Naples, Florida

Conditions: Glaucoma, Open-angle, Primary Open Angle Glaucoma (POAG)
Interventions: Nicotinamide, Standard Glaucoma Therapy; Drug · Other
Lead sponsor: University of Chicago; Other
Eligibility: 40 Years to 80 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Reduction of Small Intestinal Ulceration Risk
Interventions: Bif195, Placebo; Dietary Supplement
Lead sponsor: Chr Hansen; Industry
Eligibility: 40 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: HPV-Associated Oropharyngeal Squamous Cell Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Mediated (P16-Positive) Oropharyngeal Carcinoma by AJCC V8 Stage, HPV-Related Squamous Cell Carcinoma, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, HPV-Mediated (P16-Positive) Oropharyngeal Carcinoma by AJCC V8 Clinical Stage, HPV-Mediated (P16-Positive) Oropharyngeal Carcinoma by AJCC V8 Pathologic Stage
Interventions: NavDx HPV ctDNA Testing, Radiotherapy, Chemotherapy drug; Device · Radiation · Drug
Lead sponsor: Jonathan Schoenfeld, MD, MPH; Other
Eligibility: 22 Years and older
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2032
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Epilepsy
Interventions: Diazepam Buccal Film, Diastat® Rectal Gel (Valeant Pharmaceuticals USA); Drug
Lead sponsor: Aquestive Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 3
States / cities: Miami, Florida • Orlando, Florida • Winter Park, Florida

Conditions: Acute Heart Failure
Interventions: Sodium nitroprusside, Dobutamine, Furosemide; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Primary Four Repeat Tauopathies (4RT), Corticobasal Syndrome (CBS), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD)
Interventions: TPI 287 2 mg/m2, TPI-287 20 mg/m2, Placebo, TPI-287 6.3 mg/m2; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 50 Years to 85 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 2
States / cities: Birmingham, Alabama • San Francisco, California

Search by objective public record fields.

Safety and Efficacy of Allogeneic NK Cell Infusions in Patients With Relapsed/Refractory AML and High Risk MDS

NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone

A Study of Blood Pressure Control During Cancer Treatment

Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy

Effect of Double Dose of Alpha 1-antitrypsin Augmentation Therapy on Lung Inflammation.

A Pilot Study of Danirixin for Disease Progression in Chronic Obstructive Pulmonary Disease (COPD)

Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases

Examine the Feasibility of a Standardized Field Test for Marijuana and Alcohol Impairment: Laboratory Evaluations

An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis

BMX-001 + Paclitaxel in Adult Patients With Advanced, Recurrent, Metastatic Ovarian or Endometrial Cancer

A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors

Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer

A Randomized, Crossover Study to Assess the Effects of Dietary Fiber-containing Bars on Glucose and Insulin Responses

Intensive Combo Chemo With Autologous BM Rescue for Metastatic Breast Cancer

PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma

Efficacy of IV Palo With IV Dexamethasone vs IV Palo for Prevention of Immediate & Delayed PONV

Outcome Research to Confirm the Anti-anginal Effect of T89 in Patients With Stable Angina

Nicotinamide for Retinal Protection in Primary Open-Angle Glaucoma (NADIR Trial)

The Effect of a Probiotic Strain on Aspirin-induced GI Damage

Risk-adapted Therapy in HPV+ Oropharyngeal Cancer Using Circulating Tumor (ct)HPV DNA Profile - The ReACT Study

Diazepam Buccal Film (DBF) - Diastat Rectal Gel (DRG) Crossover Study

Intravenous Vasodilator vs. Inotropic Therapy in Patients With Heart Failure

Safety Study of TPI-287 to Treat CBS and PSP